Early molecular response in chronic myeloid leukemia and halving time: Latest evidences
详细信息 查看全文
- 作者：Massimo Breccia ; breccia@bce.uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; Matteo Molica ; Gioia Colafigli ; Fulvio Massaro ; Giuliana Alimena
- 关键词：Chronic myeloid leukemia ; Early molecular response ; Prognosis
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：48
- 期：Complete
- 页码：20-25
- 全文大小：680 K
文摘
- •
Early molecular response in CML corresponds to a ratio BCR-ABL1/ABL <10% IS at 3 months.
- •
Achievement of EMR with imatinib indicated positive long-term outcome.
- •
EMR maintain its validity with second generation TKIs as frontline treatment.
- •
Halving time indicated the kinetics of ratio BCR-ABL1/ABL decline.